|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matuo R, Sousa FG, Escargueil AE,
Grivicich I, Garcia-Santos D, Chies JA, Saffi J, Larsen AK and
Henriques JA: 5-Fluorouracil and its active metabolite FdUMP cause
DNA damage in human SW620 colon adenocarcinoma cell line. J Appl
Toxicol. 29:308–316. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matuo R, Sousa FG, Escargueil AE, Soares
DG, Grivicich I, Saffi J, Larsen AK and Henriques JA: DNA repair
pathways involved in repair of lesions induced by 5-fluorouracil
and its active metabolite FdUMP. Biochem Pharmacol. 79:147–153.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wyatt MD and Wilson DM III: Participation
of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci.
66:788–799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
El-Awady RA, Saleh EM and Dahm-Daphi J:
Targeting DNA double-strand break repair: is it the right way for
sensitizing cells to 5-fluorouracil? Anticancer Drugs. 21:277–287.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Diasio RB and Johnson MR:
Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil
clinical toxicity and tumor resistance. Clin Cancer Res.
5:2672–2673. 1999.PubMed/NCBI
|
|
9
|
Mizutani Y, Wada H, Fukushima M, Yoshida
O, Nakanishi H, Li YN and Miki T: Prognostic significance of
orotate phosphoribosyltransferase activity in bladder carcinoma.
Cancer. 100:723–731. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB and Danenberg PV: Colorectal tumors responding to
5-fluorouracil have low gene expression levels of dihydropyrimidine
dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Clin Cancer Res. 6:1322–1327. 2000.
|
|
11
|
Kolberg M, Strand KR, Graff P and
Andersson KK: Structure, function, and mechanism of ribonucleotide
reductases. Biochim Biophys Acta. 1699:1–34. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Niida H, Katsuno Y, Sengoku M, Shimada M,
Yukawa M, Ikura M, Ikura T, Kohno K, Shima H, Suzuki H, Tashiro S
and Nakanishi M: Essential role of Tip60-dependent recruitment of
ribonucleotide reductase at DNA damage sites in DNA repair during
G1 phase. Genes Dev. 24:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uziel T, Lerenthal Y, Moyal L, Andegeko Y,
Mittelman L and Shiloh Y: Requirement of the MRN complex for ATM
activation by DNA damage. EMBO J. 22:5612–5621. 2003. View Article : Google Scholar
|
|
15
|
Branzei D and Foiani M: Regulation of DNA
repair throughout the cell cycle. Nat Rev Mol Cell Biol. 9:297–308.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arnaudeau C, Lundin C and Helleday T: DNA
double-strand breaks associated with replication forks are
predominantly repaired by homologous recombination involving an
exchange mechanism in mammalian cells. J Mol Biol. 307:1235–1245.
2001. View Article : Google Scholar
|
|
17
|
Pardo B, Gomez-Gonzalez B and Aguilera A:
DNA repair in mammalian cells: DNA double-strand break repair: how
to fix a broken relationship. Cell Mol Life Sci. 66:1039–1056.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suwaki N, Klare K and Tarsounas M: RAD51
paralogs: roles in DNA damage signalling, recombinational repair
and tumorigenesis. Semin Cell Dev Biol. 22:898–905. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tashiro S, Walter J, Shinohara A, Kamada N
and Cremer T: Rad51 accumulation at sites of DNA damage and in
postreplicative chromatin. J Cell Biol. 150:283–291. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bolderson E, Richard DJ, Zhou BB and
Khanna KK: Recent advances in cancer therapy targeting proteins
involved in DNA double-strand break repair. Clin Cancer Res.
15:6314–6320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Clingen PH, Wu JY, Miller J, Mistry N,
Chin F, Wynne P, Prise KM and Hartley JA: Histone H2AX
phosphorylation as a molecular pharmacological marker for DNA
interstrand crosslink cancer chemotherapy. Biochem Pharmacol.
76:19–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Asakawa H, Koizumi H, Koike A, Takahashi
M, Wu W, Iwase H, Fukuda M and Ohta T: Prediction of breast cancer
sensitivity to neoadjuvant chemotherapy based on status of DNA
damage repair proteins. Breast Cancer Res. 12:R172010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujinaka Y, Matsuoka K, Iimori M, Tuul M,
Sakasai R, Yoshinaga K, Saeki H, Morita M, Kakeji Y, Gillespie DA,
Yamamoto K, Takata M, Kitao H and Maehara Y: ATR-Chk1 signaling
pathway and homologous recombinational repair protect cells from
5-fluorouracil cytotoxicity. DNA Repair (Amst). 11:247–258. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scharer OD: DNA interstrand crosslinks:
natural and drug-induced DNA adducts that induce unique cellular
responses. Chembiochem. 6:27–32. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Limoli CL, Giedzinski E, Bonner WM and
Cleaver JE: UV-induced replication arrest in the xeroderma
pigmentosum variant leads to DNA double-strand breaks, gamma-H2AX
formation, and Mre11 relocalization. Proc Natl Acad Sci USA.
99:233–238. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ewald B, Sampath D and Plunkett W: H2AX
phosphorylation marks gemcitabine-induced stalled replication forks
and their collapse upon S-phase checkpoint abrogation. Mol Cancer
Ther. 6:1239–1248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Johnston PG, Geoffrey F, Drake J, Voeller
D, Grem JL and Allegra CJ: The cellular interaction of
5-fluorouracil and cisplatin in a human colon carcinoma cell line.
Eur J Cancer. 32A:2148–2154. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matsusaka S, Nagareda T and Yamasaki H:
Does cisplatin (CDDP) function as a modulator of 5-fluorouracil
(5-FU) antitumor action? A study based on a clinical trial. Cancer
Chemother Pharmacol. 55:387–392. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Banath JP, Klokov D, MacPhail SH, Banuelos
CA and Olive PL: Residual gammaH2AX foci as an indication of lethal
DNA lesions. BMC Cancer. 10:42010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huehls AM, Wagner JM, Huntoon CJ, Geng L,
Erlichman C, Patel AG, Kaufmann SH and Karnitz LM: Poly
(ADP-Ribose) polymerase inhibition synergizes with
5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer
cells. Cancer Res. 71:4944–4954. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kanamaru R, Kakuta H, Sato T, Ishioka C
and Wakui A: The inhibitory effects of 5-fluorouracil on the
metabolism of preribosomal and ribosomal RNA in L-1210 cells in
vitro. Cancer Chemother Pharmacol. 17:43–46. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghoshal K and Jacob ST: Specific
inhibition of pre-ribosomal RNA processing in extracts from the
lymphosarcoma cells treated with 5-fluorouracil. Cancer Res.
54:632–636. 1994.PubMed/NCBI
|
|
33
|
Santi DV and Hardy LW: Catalytic mechanism
and inhibition of tRNA (uracil-5-) methyltransferase: evidence for
covalent catalysis. Biochemistry. 26:8599–8606. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Randerath K, Tseng WC, Harris JS and Lu
LJ: Specific effects of 5-fluoropyrimidines and 5-azapyrimidines on
modification of the 5 position of pyrimidines, in particular the
synthesis of 5-methyluracil and 5-methylcytosine in nucleic acids.
Recent Results Cancer Res. 84:283–297. 1983.PubMed/NCBI
|
|
35
|
Patton JR: Ribonucleoprotein particle
assembly and modification of U2 small nuclear RNA containing
5-fluorouridine. Biochemistry. 32:8939–8944. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Doong SL and Dolnick BJ: 5-Fluorouracil
substitution alters pre-mRNA splicing in vitro. J Biol Chem.
263:4467–4473. 1988.PubMed/NCBI
|
